GLP-1 Market
LLY $1145.46 ▼ -1.0% NVO $37.49 ▼ -1.1% PFE $28.29 ▼ -0.8% VKTX $31.28 ▼ -4.0% KLRA $10.77 ▼ -5.7% GPCR $30.27 ▼ -3.2% RHHBY $51.91 ▼ -0.7%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

native glp-1

Company
University of Aarhus
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Oct 1, 2026

Trial details
  • Completed NCT NCT01185119

    Effect of GLP-1 on Glucose Metabolism in CNS Assessed by PET

    Not yet reported, Not yet reported University of Aarhus 10 participants Est. completion 2011-03 1 site
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01677104

    The Microvascular Function of GLP-1 and Its Analogues

    Not yet reported Katarina Kos 63 participants Est. completion 2014-07 1 site
    Type 2 diabetes Other conditions: Obesity
    View official trial listing →
  • Terminated NCT NCT01934816

    Incretin and KATP Channels

    Not yet reported Katarina Kos 2 participants Est. completion 2015-10 1 site Stand-alone
    Other conditions: Healthy Subjects
    View official trial listing →
  • Completed NCT NCT01988545

    GLP-1's Effect on Cardiac Parameters and Mesenteric Blood Flow

    Not yet reported Zealand University Hospital 8 participants Est. completion 2014-12-01 1 site
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT02731664

    GLP-1 Inhibits Prandial Antro-duodeno-jejunal Motility in Humans

    Not yet reported Uppsala University 12 participants Est. completion 2017-08 1 site
    Other conditions: Functional Gastrointestinal Disorders
    View official trial listing →
  • Not yet recruiting NCT NCT07614412

    SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes.

    Not yet reported Ministry of Health, Saudi Arabia 240 participants Est. completion 2028-12-31 1 site Added to GLP-1
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: native glp-1, native glp-1 (7-36)

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.